Massachusetts Financial Services Co. MA Has $953.14 Million Stock Position in Qiagen (NYSE:QGEN)

Massachusetts Financial Services Co. MA trimmed its holdings in Qiagen (NYSE:QGEN) by 0.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,196,437 shares of the company’s stock after selling 56,175 shares during the period. Massachusetts Financial Services Co. MA owned about 10.16% of Qiagen worth $953,142,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Riverview Trust Co purchased a new position in Qiagen during the 1st quarter worth $28,000. Park Place Capital Corp purchased a new position in Qiagen during the first quarter worth about $36,000. Quarry LP bought a new stake in Qiagen in the 4th quarter worth about $38,000. CWM LLC grew its position in Qiagen by 19.1% in the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after purchasing an additional 358 shares in the last quarter. Finally, Headlands Technologies LLC increased its stake in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after buying an additional 2,189 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

NYSE QGEN opened at $46.36 on Monday. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 0.27. The company has a market cap of $10.58 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 3.25 and a beta of 0.39. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.44. The firm’s 50-day simple moving average is $44.45 and its two-hundred day simple moving average is $43.40.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.03. The company had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.53 earnings per share. Research analysts predict that Qiagen will post 2.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a report on Thursday, June 27th. Robert W. Baird upped their price objective on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.10.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.